The CHARM program: Enhancement of RAAS manipulation in heart failure
Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors1
in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF). The results have translated into benefits in clinical practice, including reductions in death from HF.5
However, the prevalence of HF continues to increase. This may be a consequence of an aging population with high rates of hypertension and ischemic heart disease.6
Many of these patients have preserved LVEF, but all are at risk for hospitalization and cardiovascular (CV) death.
The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program included three parallel, independent, randomized, double-blind comparisons of the angiotensin-receptor blocker (ARB) candesartan with placebo. The trials tested whether candesartan would reduce mortality and morbidity in a broad range of patients with HF.7
References are listed at the end of the Data Alert.
Download 04DA_CHARM.ppt (7 slides - 1.4MB)